Creating a nasal vaccine to prevent gonorrhea
Official title: DEVELOPMENT OF AN INTRANASAL VACCINE AGAINST GONORRHEA
Funded at Intravacc B.v. · NIH-10919579 · Data updated 2026-11-12
This study is working on a new nose spray vaccine to help prevent gonorrhea, a common sexually transmitted infection, and if it works well in tests, it could offer a simple way to protect people from getting this infection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Intravacc B.v. NIH-funded |
| Lab location | 1 site (Bilthoven, Netherlands) |
| Project start | September 21, 2022 |
| Project end | January 14, 2026 |
| Funding year | 2023 |
| Award (this year) | $756,750 |
| NIH project number | 75N93022C00058-P00002-9999-1 |
| Project ID | NIH-10919579 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of gonorrhea infection, including sexually active adults and adolescents.
✕Less likely to help
Patients who are not sexually active or those who have already been vaccinated against gonorrhea may not benefit from this research.
What this research studies
This research focuses on developing an intranasal vaccine aimed at preventing gonorrhea, a common sexually transmitted infection. The approach involves formulating and manufacturing vaccine components, followed by rigorous testing for safety and effectiveness in animal models. If successful, this vaccine could provide a non-invasive method for immunization against gonorrhea, potentially reducing the incidence of this infection in the population.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective vaccine that helps prevent gonorrhea infections.
How similar studies have gone: While there have been successful vaccine developments for other infectious diseases, this specific approach for gonorrhea is relatively novel and untested.
Where this research is happening
-
Intravacc B.v.
Bilthoven, Netherlands Active
Researchers
- Principal investigator: Oosterhoff, Dinja — Intravacc B.v.
- Study coordinator: Oosterhoff, Dinja
Related research
Other NIH-funded projects on the same topics.
-
Developing a vaccine for a serious childhood illness caused by a virus.
This study is working on a new vaccine to help protect children from Acute Flaccid Myelitis (AFM), a serious condition linked to a virus, and it aims to eventually test the vaccine's safety and effectiveness in kids.
-
Developing vaccines to combat antibiotic-resistant infections and bioterrorism threats
This study is working on new vaccines to help protect against infections from tough bacteria that don't respond to regular antibiotics, and it's aimed at making sure these vaccines are safe and effective for people when they need them most.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.